PRAME 425-433 (HLA-A*02:01)
( SLLQHLIGL )
PRAME 425-433 (SLLQHLIGL) is a linear peptidic epitope (epitope ID 459114) studied as part of Preferentially Expressed Antigen in Melanoma (PRAME, UniProt:P78395), a cancer/testis antigen from Homo sapiens. PRAME is highly expressed in several solid tumors such as melanoma, epithelial ovarian cancer, multiple sarcoma subtypes and non-small cell lung cancer, while in healthy tissue it is almost exclusively restricted to the testicles. Therefore, it is a promising target for adoptive T cell therapies.
PRAME 425-433 (SLLQHLIGL) was first described by Kessler et al. in 2001. In their experiments, cytotoxic T lymphocytes recognizing the high affinity binding, HLA-A*0201–restricted PRAME epitope specifically lysed melanoma, renal cell, lung, mammary, and cervical carcinoma cell lines.
Sequence: | SLLQHLIGL | |
Gene: | PRAME | |
Delivery: | 2-3 days | |
C-Terminus: | OH | |
N-Terminus: | H | |
Amount: | 1 mg | |
Counter Ion: | TFA | |
Protein: | Melanoma antigen preferentially expressed in tumors | |
Species: | Human | |
Allele: | HLA-A*02:01 | |
Application : | Flow Cytometry | |
Indication : | Cancer, Immunology | |
Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:Kessler, J H et al. “Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.” The Journal of experimental medicine vol. 193,1 (2001): 73-88. doi:10.1084/jem.193.1.73
€63.50*
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS